U.S., April 8 -- ClinicalTrials.gov registry received information related to the study (NCT07514052) titled 'Predicting Response to Selinexor-Based Therapy in Relapsed/Refractory Multiple Myeloma: A Multicenter Prospective Study' on March 22.
Brief Summary: Background:
Relapsed/refractory multiple myeloma (RRMM) remains a major clinical challenge due to treatment resistance and disease heterogeneity. Selinexor-based regimens have demonstrated promising efficacy; however, predictive biomarkers for treatment response are still lacking. This study aims to evaluate the predictive value of differential multigene expression in RRMM patients treated with selinexor-based therapy.
Methods:
This is a multicenter, prospective clinical study enroll...